vs

Side-by-side financial comparison of Prime Medicine, Inc. (PRME) and ZenaTech, Inc. (ZENA). Click either name above to swap in a different company.

ZenaTech, Inc. is the larger business by last-quarter revenue ($941.9K vs $838.0K, roughly 1.1× Prime Medicine, Inc.).

Prime Medicine, Inc. is an American biotechnology company developing gene therapies based on prime editing. The company is headquartered in Cambridge, Massachusetts.

ZenaTech, Inc. is a technology firm specializing in AI-integrated drone solutions and enterprise SaaS platforms for industrial and public sector clients. Its core offerings include purpose-built drone hardware, fleet management tools, and actionable data analytics, serving key markets such as public safety, infrastructure inspection, agriculture, and logistics across North America.

PRME vs ZENA — Head-to-Head

Bigger by revenue
ZENA
ZENA
1.1× larger
ZENA
$941.9K
$838.0K
PRME

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
PRME
PRME
ZENA
ZENA
Revenue
$838.0K
$941.9K
Net Profit
$-46.1M
Gross Margin
Operating Margin
-5800.5%
Net Margin
-5498.7%
Revenue YoY
-61.6%
Net Profit YoY
-9.0%
EPS (diluted)
$-0.22
$-0.49

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PRME
PRME
ZENA
ZENA
Q4 25
$838.0K
Q3 25
$1.2M
$941.9K
Q2 25
$1.1M
$702.6K
Q1 25
$1.5M
$431.7K
Q4 24
$2.2M
Q3 24
$820.1K
Q2 24
$0
Q1 24
$591.0K
Net Profit
PRME
PRME
ZENA
ZENA
Q4 25
$-46.1M
Q3 25
$-50.6M
Q2 25
$-52.6M
Q1 25
$-51.9M
Q4 24
$-42.3M
Q3 24
Q2 24
$-55.3M
Q1 24
$-45.8M
Operating Margin
PRME
PRME
ZENA
ZENA
Q4 25
-5800.5%
Q3 25
-4406.0%
Q2 25
-4787.2%
Q1 25
-3603.3%
Q4 24
-2025.7%
Q3 24
Q2 24
Q1 24
-8179.5%
Net Margin
PRME
PRME
ZENA
ZENA
Q4 25
-5498.7%
Q3 25
-4129.1%
Q2 25
-4716.7%
Q1 25
-3568.8%
Q4 24
-1936.6%
Q3 24
Q2 24
Q1 24
-7743.0%
EPS (diluted)
PRME
PRME
ZENA
ZENA
Q4 25
$-0.22
Q3 25
$-0.32
$-0.49
Q2 25
$-0.41
$-0.01
Q1 25
$-0.40
Q4 24
$-0.31
Q3 24
Q2 24
$-0.46
Q1 24
$-0.44

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PRME
PRME
ZENA
ZENA
Cash + ST InvestmentsLiquidity on hand
$63.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$120.9M
Total Assets
$342.7M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PRME
PRME
ZENA
ZENA
Q4 25
$63.0M
Q3 25
$71.4M
Q2 25
$53.8M
Q1 25
$91.9M
Q4 24
$182.5M
Q3 24
Q2 24
$55.6M
Q1 24
$94.2M
Stockholders' Equity
PRME
PRME
ZENA
ZENA
Q4 25
$120.9M
Q3 25
$161.8M
Q2 25
$60.9M
Q1 25
$106.9M
Q4 24
$153.1M
Q3 24
Q2 24
$196.6M
Q1 24
$243.8M
Total Assets
PRME
PRME
ZENA
ZENA
Q4 25
$342.7M
Q3 25
$385.0M
Q2 25
$279.0M
Q1 25
$328.2M
Q4 24
$297.5M
Q3 24
Q2 24
$259.7M
Q1 24
$311.4M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PRME
PRME
ZENA
ZENA
Operating Cash FlowLast quarter
$-37.3M
$-3.1M
Free Cash FlowOCF − Capex
$-37.5M
FCF MarginFCF / Revenue
-4480.4%
Capex IntensityCapex / Revenue
34.6%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-167.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PRME
PRME
ZENA
ZENA
Q4 25
$-37.3M
Q3 25
$-35.0M
$-3.1M
Q2 25
$-41.4M
$-941.0K
Q1 25
$-48.9M
$-396.2K
Q4 24
$16.2M
Q3 24
$-3.1M
Q2 24
$-45.5M
Q1 24
$-67.7M
Free Cash Flow
PRME
PRME
ZENA
ZENA
Q4 25
$-37.5M
Q3 25
$-35.3M
Q2 25
$-43.0M
Q1 25
$-51.3M
Q4 24
$14.5M
Q3 24
Q2 24
$-47.4M
Q1 24
$-70.0M
FCF Margin
PRME
PRME
ZENA
ZENA
Q4 25
-4480.4%
Q3 25
-2880.5%
Q2 25
-3855.1%
Q1 25
-3526.8%
Q4 24
662.1%
Q3 24
Q2 24
Q1 24
-11849.6%
Capex Intensity
PRME
PRME
ZENA
ZENA
Q4 25
34.6%
Q3 25
20.2%
Q2 25
141.0%
Q1 25
166.6%
Q4 24
82.0%
Q3 24
Q2 24
Q1 24
393.2%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons